Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2023-08-25 Director's Dealing
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Aprea Therapeutics, Inc. dated August 23, 2023. It reports the resignation and appointment of directors and officers, specifically the resignation of Christian S. Schade and the appointment of Richard Peters as Chairperson and Dr. Jean-Pierre Bizzari as a director. It also includes the submission of matters to a vote of security holders at the 2023 annual meeting, detailing the election results of directors and ratification of the independent auditor. The content focuses on changes in the company's board of directors and senior management, which aligns with the category for Board/Management Information (MANG). The document is not an annual report, earnings release, or proxy statement but a current report on management changes and voting results. Therefore, the appropriate classification is MANG with high confidence.
2023-08-24 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.